Transparency Market Research Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 2019
Published Date 21-Oct-2013
98 Page Report
Buy Now
Request Sample
Press Release
Erectile Dysfunction Drugs Market is Expected to Reach USD 3.4 Billion Globally in 2019: Transparency Market Research Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Erectile Dysfunction Drugs Market
REPORT DESCRIPTION
Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 According to a new market report published by Transparency Market Research "Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) -Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global erectile dysfunction drugs market was valued at USD 4.3 billion in 2012 and is expected to decline at a CAGR of (4.5%) from 2013 to 2019, to reach an estimated value of USD 3.4 billion in 2019. Browse the full report with complete TOC at http://www.transparencymarketresearch.com/erectiledysfunction-drugs.html Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. Erectile dysfunction is a common medical disorder primarily affecting men older than 40 years of age. In addition, other than the typical causes of erectile dysfunction, such as diabetes and hypertension, a number of common lifestyle related factors are also associated with development of the condition. These include obesity, excessive alcohol consumption, smoking, use of recreational drugs, and poor physical and psychological health. Commonly, oral drugs belonging to the PDE 5 inhibitors class form the mainstay of erectile dysfunction treatment. Other treatment options include lifestyle modification, testosterone therapy, penile devices, injection therapies and psychotherapy. The global market for erectile dysfunction drugs has been studied from the perspective of currently marketed branded drugs and pipeline drugs. Branded drugs include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), MUSE (medicated urethral systems for erection), Mvix (mirodenafil) and Helleva (lodenafil). The drugs in the pipeline for erectile dysfunction treatment primarily consist of two major drugs, namely Vitaros (alprostadil) and Uprima (apomorphine) currently in later phases of clinical trials. In 2012, Viagra (sildenafil citrate) accounted for the largest share (45%) by revenue of the total erectile dysfunction drugs market. However, due to the loss of the drug's patent exclusivity in Europe and other countries in 2013, the overall market revenue is expected to decline during the forecast period as international markets contribute considerably to the overall market revenue of the drug. In the U.S.
Transparency Market Research
2
Erectile Dysfunction Drugs Market
market, Viagra will continue to maintain a major revenue share due to its extended patent exclusivity till 2020. The market for Cialis (tadalafil) accounted for the second largest share at USD 1,926.8 million, in 2012. However, it is expected to witness a decline in market revenue at a CAGR of (12.6%) from 2013 to 2019, owing to loss of patent exclusivity in 2017. In addition, the patent for Bayer's Levitra/Staxyn (vardenafil) is scheduled to expire in 2018 and is thus expected to contribute to the declining market revenue. A few novel compounds are currently under investigation in both preclinical and clinical settings, for the treatment of impotency. These studies are majorly focused on medications with improved efficacy, shorter onset of action and fewer side effects as compared to the currently available treatments. Such pipeline drugs include Vitaros (alprostadil), Uprima (apomorphine) and Topiglan (alprostadil), amongst others. Geographically, North America dominated the global market for erectile dysfunction drugs in terms of revenue generation and is expected to maintain its position throughout the forecast period. The extended patent exclusivity for Pfizer's Viagra (sildenafil citrate) in the U.S., till 2020, will be responsible for the leadership of the North American market. Europe was the second largest regional market for erectile dysfunction drugs in 2012, owing to the increased demand for ED drugs. Market growth will also be facilitated by the expected marketing approvals for a few promising drug candidates such as Stendra/Spedra (avanafil) and Zydena (udenafil) by mid 2014. The global erectile dysfunction dugs market is dominated by few major players including Pfizer, Inc. Eli Lilly & Co., and Bayer AG. Post patent expiration of the major branded drugs and intense genericization of the market, the competition in this market is expected to be characterized by consolidation activities, partnerships, and intensive mergers and acquisitions. The other key players in the erectile dysfunction drugs market include Dong-A Pharmaceutical Co. Ltd., Vivus, Inc., Apricus Biosciences, Inc. and Meda Pharmaceuticals The global erectile dysfunction drugs market is segmented as follows: Erectile Dysfunction Drugs Market, by Major Branded Products
•
Viagra
•
Cialis
•
Levitra/Staxyn
Transparency Market Research
3
Erectile Dysfunction Drugs Market
•
Stendra/Spedra
•
Zydena
•
MUSE
•
Mvix
•
Helleva
Erectile Dysfunction Drugs Market, Pipeline Analysis
•
Vitaros
•
Uprima
•
Others
•
Topiglan
•
Melanocortin Activators
•
Gene Therapy
Erectile Dysfunction Drugs Market, by Geography
•
North America
•
Europe
•
Asia-Pacific
•
Rest of the World (RoW) Browse the full report with complete TOC at http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html
TABLE OF CONTENT
Transparency Market Research
4
Erectile Dysfunction Drugs Market
Table of Content
Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 List of Abbreviations
Chapter 2 Executive Summary
Chapter 3 Market Overview 3.1 Introduction to Erectile Dysfunction 3.2 Current Market Trends and Future Outlook 3.2.1 Impact of Generics 3.2.2 Key Patent Expirations 3.2.3 Ongoing Clinical Trials in the U.S. for ED Treatment (Phase III) 3.3 Types of Treatments for ED 3.3.1 Phosphodiesterase Type 5 Inhibitors (PDE 5 Inhibitors) 3.3.2 Localized Therapy 3.3.3 Testosterone Replacement Therapy
Transparency Market Research
5
Erectile Dysfunction Drugs Market
3.3.4 Vacuum Constriction Devices 3.3.5 Surgery (Penile Implants and Vascular Surgery) 3.3.6 Alternative Medicines (Yohimbine and Other Herb and Dietary Supplements) 3.4 Market Drivers 3.4.1 Increase in Elderly Population 3.4.2 Increasing Global Incidence of Various Diseases and Growing Preference Towards Sedentary Lifestyle 3.4.3 Increase in Awareness and Patient Education 3.5 Market Restraints 3.5.1 Prevalence of Sexually Transmitted Diseases with ED Drug Users 3.5.2 Narrowing of Insurance Coverage for Erectile Dysfunction Treatment 3.5.3 Growing Threat from Counterfeit Drugs 3.6 Market Opportunities 3.6.1 Novel Molecule Combinations and Drug Delivery Techniques are Expected to Become a Rising Opportunity 3.6.2 Generics - A Growing Global Opportunity 3.7 Porter’s Five Forces Analysis: Global Erectile Dysfunction Drugs Market 3.7.1 Bargaining Power of Suppliers 3.7.2 Bargaining Power of Buyers 3.7.3 Threat of Substitutes 3.7.4 Threat of New Entrants 3.7.5 Competitive Rivalry
Transparency Market Research
6
Erectile Dysfunction Drugs Market
3.8 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)
Chapter 4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million) 4.1 Market Overview 4.1.1 Mechanism of Action 4.1.2 Characteristics of Major Phosphodiesterase Type 5 Inhibitors 4.2 Viagra (Sildenafil Citrate) 4.2.1 Introduction 4.2.2 Global Viagra Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million) 4.2.3 Patent Expiration and Regulatory Scenario 4.2.3.1 The U.S. Market 4.2.3.2 International Market 4.2.4 Past & Current Market Scenario 4.2.5 Global Viagra Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million) 4.2.6 Future Market Scenario 4.2.7 Global Viagra Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million) 4.3 Cialis (Tadalafil) 4.3.1 Introduction 4.3.2 Global Cialis Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million) 4.3.3 Patent and Regulatory Scenario
Transparency Market Research
7
Erectile Dysfunction Drugs Market
4.3.4 Current Market Scenario and Patent Expiry Effect 4.3.5 Global Cialis Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million) 4.3.6 Future Market Scenario 4.3.7 Global Cialis Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million) 4.4 Levitra/Staxyn (Vardenafil) 4.4.1 Introduction 4.4.2 Global Levitra/Staxyn Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million) 4.4.3 Patent and Regulatory Scenario 4.4.4 Current and Future Market Scenario 4.4.5 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million) 4.4.6 Global Levitra/Staxyn Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million) 4.5 Stendra/Spedra (Avanafil) 4.5.1 Introduction 4.5.2 Future Market Scenario 4.5.3 Global Stendra/Spedra Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million) 4.6 Zydena (Udenafil) 4.6.1 Introduction 4.6.2 Global Zydena Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million) 4.6.3 Current Market Scenario 4.6.4 Global Zydena Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million) 4.6.5 Future Market Scenario
Transparency Market Research
8
Erectile Dysfunction Drugs Market
4.6.6 Global Zydena Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million) 4.7 MUSE (Medicated Urethral System for Erection) 4.7.1 Patent and Regulatory Scenario 4.8 Mvix (Mirodenafil) 4.9 Helleva (Lodenafil Carbonate)
Chapter 5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis 5.1 Overview 5.2 Vitaros (Alprostadil) 5.2.1 Global Vitaros Market for Erectile Dysfunction Treatment, 2014 – 2019 (USD Million) 5.3 Uprima (Apomorphine) 5.4 Others (Topiglan, Melanocortin Activators, Gene Therapy) 5.4.1 Topiglan 5.4.2 Melanocortin Activators 5.4.3 Gene Therapy
Chapter 6 Global Erectile Dysfunction Drugs Market, By Geography 6.1 Overview 6.1.1 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2010 – 2019 (USD Million) 6.1.2 Comparative Analysis: Global Erectile Dysfunction Drugs Market, By Geography, 2012 & 2019 (Value %)
Transparency Market Research
9
Erectile Dysfunction Drugs Market
6.2 North America 6.2.1 North America Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million) 6.2.2 North America Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million) 6.3 Europe 6.3.1 Europe Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million) 6.3.2 Europe Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million) 6.4 Asia-Pacific 6.4.1 Asia-Pacific Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million) 6.4.2 Asia-Pacific Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million) 6.5 Rest of the World (Row) 6.5.1 Rest of the World (Row) Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million) 6.5.2 Rest of the World (Row) Erectile Dysfunction Drugs Market, 2015 – 2019 (USD Million)
Chapter 7 Competitive Landscape 7.1 Market Share Analysis: Global Erectile Dysfunction Drugs Market, 2012 (%) 7.1.1 Methodology 7.1.2 Analysis
Chapter 8 Recommendations 8.1 Novel Drug Formulations and Genericization owing to Patent Expiration of well recognized ED Drugs 8.2 Mergers and Acquisitions to Strengthen Market Presence
Transparency Market Research
10
Erectile Dysfunction Drugs Market
8.3 Cost Containment Measures
Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html Chapter 9 Company Profiles 9.1 Apricus Biosciences, Inc. 9.1.1 Company Overview 9.1.2 Business Strategies 9.1.3 Financial Overview 9.1.4 Product Portfolio 9.1.5 Recent Developments 9.2 Bayer AG 9.2.1 Company Overview 9.2.2 Business Strategies 9.2.3 Financial Overview 9.2.4 Product Portfolio 9.2.5 Recent Developments 9.3 Cristalia Produtos Quimicos Farmaceuticos Ltda. 9.3.1 Company Overview 9.3.2 Business Strategies 9.3.3 Product Portfolio 9.3.4 Recent Developments
Transparency Market Research
11
Erectile Dysfunction Drugs Market
9.4 Dong-A Pharmaceutical Co. Ltd. 9.4.1 Company Overview 9.4.2 Business Strategies 9.4.3 Financial Overview 9.4.4 Product Portfolio 9.4.5 Recent Developments 9.5 Eli Lilly And Company 9.5.1 Company Overview 9.5.2 Business Strategies 9.5.3 Financial Overview 9.5.4 Product Portfolio 9.5.5 Recent Developments 9.6 Meda Pharmaceuticals, Inc. 9.6.1 Company Overview 9.6.2 Business Strategies 9.6.3 Product Portfolio 9.6.4 Recent Developments 9.7 Pfizer, Inc. 9.7.1 Company Overview 9.7.2 Business Strategies 9.7.3 Financial Overview
Transparency Market Research
12
Erectile Dysfunction Drugs Market
9.7.4 Product Portfolio 9.7.5 Recent Developments 9.8 S.K. Chemicals Co. Ltd. 9.8.1 Company Overview 9.8.2 Business Strategies 9.8.3 Financial Overview 9.8.4 Product Portfolio 9.8.5 Recent Developments 9.9 Vivus, Inc. 9.9.1 Company Overview 9.9.2 Business Strategies 9.9.3 Financial Overview 9.9.4 Product Portfolio 9.9.5 Recent Developments Browse the full report with complete TOC at http://www.transparencymarketresearch.com/erectiledysfunction-drugs.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers.
Transparency Market Research
13
Erectile Dysfunction Drugs Market
We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/
Transparency Market Research
14